FHIT和Livin在非小细胞肺癌中的表达及临床意义

doi:10.3969/j.issn.1002-3070.2011.02.009

Abstract

Abstract:

Objective To observe expressions of FHIT and Livin in human non-small cell lung cancer(NSCLC)and investigate correlation and clinical significance between FHIT,Livin expression and infiltration,metastasis of NSCLC.Methods The expressions of FHIT and Livin protein in 60 cases of lung cancer and 19 cases of normal lung tissue were detected by SP immunohistochemistry method,and the clinicalpathology features of lung cancer were analyzed statistically.Results Compared with normal lung tissues,there was down-regulation of FHIT expression in NSCLC tissues(P＜0.05),as well as up-regulation of Livin expression in NSCLC tissues(P＜0.05).FHIT and Livin expression had close relationship with pathology type,cell differentiation degree,metastasis and TNM staging(P＜0.05).FHIT and Livin expression had no relationship with patient' age,sex,tumor location and tumor size(P＞0.05).Conclusion FHIT and Livin expression can be conducted as specific index to NSCLC prognosis.It will provide a new target to tumor gene therapy.

Key words: Non-small cell lung cancer, FHIT, Livin, Immunohistochemistry

CLC Number:

R734.2

ZHANG Shuang, WANG Yan, LIU Jinglei. The expression and clinical significance of FHIT protein and Livin protein in non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(2): 136-140.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.3969/j.issn.1002-3070.2011.02.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2011/V25/I2/136

[1]	LU Juping, HU Jun, DENG Yongming, LIAO Shufang. Downregulation of FKBP4 inhibits the malignant progression of non-small cell lung cancer by blocking the PI3K/Akt/mTOR signaling pathway [J]. Journal of Practical Oncology, 2025, 39(3): 184-190.
[2]	LI Caizheng, ZHENG Jing, SU Qiaoli. Advance progress in immunotherapy for unresectable locally advanced non-small cell lung cancer [J]. Journal of Practical Oncology, 2025, 39(1): 67-72.
[3]	HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(5): 306-312.
[4]	XU Lingyan, LI Qianni, LI Jian, YAO Xuepei, LIU Meina. Analysis for the impact of the first hospitalization days on treatment quality in patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(4): 221-226.
[5]	YAO Xuepei, BAI Shanqi, LIU Meina. Analysis of factors influencing treatment quality of non-small cell lung cancer based on causal diagram model [J]. Journal of Practical Oncology, 2024, 38(4): 227-234.
[6]	LI Jian, LI Qianni, XU Lingyan, YAO Xuepei, LIU Meina. Research on the causal effects of non-small cell lung cancer treatment process on in-hospital mortality based on double robust estimation method [J]. Journal of Practical Oncology, 2024, 38(4): 235-240.
[7]	CHENG Yongming, DONG Huanhuan, XU Hui. Hsa-let-7b-5p inhibits proliferation,migration and invasion in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(3): 157-167.
[8]	ZHANG Xuan, LI Xin, ZHAO Kang. Relationship between serum inflammatory markers and prognosis of advanced non-small cell lung cancer patients treated with first-line immunosuppressants [J]. Journal of Practical Oncology, 2024, 38(1): 37-44.
[9]	MIAO Ling, ZHAO Zhihan, WANG Min. Levels and clinical significance of PA28γ and miR-7-5p in tumor tissues of patients with non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 344-350.
[10]	CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 383-388.
[11]	CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation [J]. Journal of Practical Oncology, 2023, 37(3): 262-266.
[12]	LONG Chaolian, LI Kun, LIU Zichen, ZHANG Nana, CHE Nanying. The correlation between the expression of programmed death ligand 1 in non-small cell lung cancer and clinical pathological features and common driver gene mutation [J]. Journal of Practical Oncology, 2023, 37(2): 117-122.
[13]	LI Saiyang, BAO Junjie, QU Guofan. Research progress on clinicopathological and genetic alterations of liposarcoma [J]. Journal of Practical Oncology, 2023, 37(1): 83-86.
[14]	XU Zihan, YU Guohua, NIE Yuhui, SUN Mengmeng, FENG Hui, LIU Shuzhen. Predictive effect of peripheral blood markers on immune-related adverse reactions of advanced non-small cell lung cancer and their correlation with survival outcome [J]. Journal of Practical Oncology, 2022, 36(6): 544-550.
[15]	ZHU Kaibin, HE Changjun, CHEN Lantao, KONG Xianglong, ZHAO Su, XU Shidong. Tumor-associated macrophages promotes non-small cell lung cancer growth and tumor vascularization via PLGF/Flt-1 and TGF-β1 signal pathway [J]. Journal of Practical Oncology, 2022, 36(5): 391-397.

The expression and clinical significance of FHIT protein and Livin protein in non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments